成都天视珍生物技术

Chengdu Tianshizhen Biotechnology is a specialized biotechnology company based in China and operates as a key subsidiary of Sichuan Kelun-Biotech Biopharmaceutical. The company is dedicated to the discovery and development of high-value biologics, with a primary focus on oncology and immunology. Its research portfolio is highlighted by advanced antibody-drug conjugates (ADCs) and monoclonal antibodies designed to address unmet medical needs in various cancers. The lead program, A166, is a HER2-targeted ADC that has demonstrated significant efficacy in clinical trials for HER2-positive breast cancer and is currently under regulatory review in China. Tianshizhen benefits from the integrated R&D and manufacturing capabilities of the Kelun Pharmaceutical Group, enabling rapid translation from laboratory to clinic.